Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU.
ADAMTS13 Protein
/ blood
Aged
Aged, 80 and over
Biomarkers
Blood Proteins
/ analysis
COVID-19
/ blood
Cross-Sectional Studies
Endothelium, Vascular
/ metabolism
Extracorporeal Circulation
Female
Fibrinolysin
/ biosynthesis
Fibrinolysis
Hemostasis
Heparin
/ therapeutic use
Humans
Intensive Care Units
Male
Middle Aged
Partial Thromboplastin Time
Prognosis
SARS-CoV-2
/ isolation & purification
Thrombin
/ biosynthesis
von Willebrand Factor
/ analysis
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
pubmed:
15
1
2021
medline:
14
5
2021
entrez:
14
1
2021
Statut:
ppublish
Résumé
Respiratory failure in coronavirus disease 2019 (COVID-19) patients is one of the most frequent causes for referral to the ICU. A significant percentage of these patients does not survive the infection due to thromboembolic complications. Furthermore, the vascular system seems also to be involved in the pathogenesis. To investigate the role of hemostasis and endothelium on the outcome of COVID-19 patients admitted to the ICU. Blood was drawn from 16 ICU COVID-19 patients for hemostatic analysis. Patients were followed-up till discharge (n = 11) or death (n = 5). Parameters related to both coagulation and fibrinolysis, though disturbed, were not associated with mortality. Contrarily, activated Von Willebrand factor was increased and ADAMTS13 levels were decreased by two-fold in nonsurvivors compared with survivors. Our data established the involvement of the Von Willebrand factor-ADAMTS13 axis in the COVID-19 pathogenesis, thereby demonstrating that these plasma proteins seem to be strong predictors for ICU mortality.
Identifiants
pubmed: 33443932
doi: 10.1097/MBC.0000000000001007
pii: 00001721-202106000-00009
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
von Willebrand Factor
0
Heparin
9005-49-6
Thrombin
EC 3.4.21.5
Fibrinolysin
EC 3.4.21.7
ADAMTS13 Protein
EC 3.4.24.87
ADAMTS13 protein, human
EC 3.4.24.87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-293Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18:844–847.
Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost 2020; 18:786–787.
Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect 2020; 35:100679.
Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med 2020; 383:288–290.
Escher R, Breakey N, Lammle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res 2020; 190:62.
Kremers RM, Wagenvoord RJ, Hemker HC. The effect of fibrin(ogen) on thrombin generation and decay. Thromb Haemost 2014; 112:486–494.
van der Vorm LN, Li L, Huskens D, Chayouâ W, Kelchtermans H, de Groot PG, et al. Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor. PLoS One 2019; 14:e0211961.
Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4–15.
Kremers RMW, Kleinegris MC, Ninivaggi M, de Laat B, Ten Cate H, Koek GH, et al. Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis. PLoS One 2017; 12:e0177020.
Miszta A, Kopec AK, Pant A, Holle LA, Byrnes JR, Lawrence DA, et al. A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice. Blood 2020; 135:1704–1717.
Stulnig TM. C-reactive protein, fibrinogen, and cardiovascular risk. N Engl J Med 2013; 368:84–85.
Haberichter SL. von Willebrand factor propeptide: biology and clinical utility. Blood 2015; 126:1753–1761.
Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21:731–738.
Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112:11–18.